Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Case 36-2018: A 29-Year-Old Man with an Incidentally Discovered Renal Mass.

Dahl DM, Simeone JF, Iliopoulos O, Saylor PJ, Wu CL.

N Engl J Med. 2018 Nov 22;379(21):2064-2072. doi: 10.1056/NEJMcpc1802832. No abstract available.

PMID:
30462933
2.

Negative regulation of EGFR signalling by the human folliculin tumour suppressor protein.

Laviolette LA, Mermoud J, Calvo IA, Olson N, Boukhali M, Steinlein OK, Roider E, Sattler EC, Huang D, Teh BT, Motamedi M, Haas W, Iliopoulos O.

Nat Commun. 2017 Jun 28;8:15866. doi: 10.1038/ncomms15866.

3.

Early onset renal cell carcinoma in an adolescent girl with germline FLCN exon 5 deletion.

Schneider M, Dinkelborg K, Xiao X, Chan-Smutko G, Hruska K, Huang D, Sagar P, Harisinghani M, Iliopoulos O.

Fam Cancer. 2018 Jan;17(1):135-139. doi: 10.1007/s10689-017-0008-8.

PMID:
28623476
4.

Glutaminase and poly(ADP-ribose) polymerase inhibitors suppress pyrimidine synthesis and VHL-deficient renal cancers.

Okazaki A, Gameiro PA, Christodoulou D, Laviollette L, Schneider M, Chaves F, Stemmer-Rachamimov A, Yazinski SA, Lee R, Stephanopoulos G, Zou L, Iliopoulos O.

J Clin Invest. 2017 May 1;127(5):1631-1645. doi: 10.1172/JCI87800. Epub 2017 Mar 27.

5.

Assessment of Overall Survival, Quality of Life, and Safety Benefits Associated With New Cancer Medicines.

Salas-Vega S, Iliopoulos O, Mossialos E.

JAMA Oncol. 2017 Mar 1;3(3):382-390. doi: 10.1001/jamaoncol.2016.4166.

PMID:
28033447
6.

Metabolic requirements for cancer cell proliferation.

Keibler MA, Wasylenko TM, Kelleher JK, Iliopoulos O, Vander Heiden MG, Stephanopoulos G.

Cancer Metab. 2016 Aug 18;4:16. doi: 10.1186/s40170-016-0156-6. eCollection 2016.

7.

Loss of vhl in the zebrafish pronephros recapitulates early stages of human clear cell renal cell carcinoma.

Noonan HR, Metelo AM, Kamei CN, Peterson RT, Drummond IA, Iliopoulos O.

Dis Model Mech. 2016 Aug 1;9(8):873-84. doi: 10.1242/dmm.024380.

8.

HIF2a inhibitors for the treatment of VHL disease.

Metelo AM, Noonan H, Iliopoulos O.

Oncotarget. 2015 Sep 15;6(27):23036-7. Review. No abstract available.

9.

Hypoxia drives transient site-specific copy gain and drug-resistant gene expression.

Black JC, Atabakhsh E, Kim J, Biette KM, Van Rechem C, Ladd B, Burrowes PD, Donado C, Mattoo H, Kleinstiver BP, Song B, Andriani G, Joung JK, Iliopoulos O, Montagna C, Pillai S, Getz G, Whetstine JR.

Genes Dev. 2015 May 15;29(10):1018-31. doi: 10.1101/gad.259796.115.

10.

Pharmacological HIF2α inhibition improves VHL disease-associated phenotypes in zebrafish model.

Metelo AM, Noonan HR, Li X, Jin Y, Baker R, Kamentsky L, Zhang Y, van Rooijen E, Shin J, Carpenter AE, Yeh JR, Peterson RT, Iliopoulos O.

J Clin Invest. 2015 May;125(5):1987-97. doi: 10.1172/JCI73665. Epub 2015 Apr 13.

11.

Clusterin glycopeptide variant characterization reveals significant site-specific glycan changes in the plasma of clear cell renal cell carcinoma.

Gbormittah FO, Bones J, Hincapie M, Tousi F, Hancock WS, Iliopoulos O.

J Proteome Res. 2015 Jun 5;14(6):2425-36. doi: 10.1021/pr501104j. Epub 2015 May 11.

PMID:
25855029
12.

Comparative studies of the proteome, glycoproteome, and N-glycome of clear cell renal cell carcinoma plasma before and after curative nephrectomy.

Gbormittah FO, Lee LY, Taylor K, Hancock WS, Iliopoulos O.

J Proteome Res. 2014 Nov 7;13(11):4889-900. doi: 10.1021/pr500591e. Epub 2014 Sep 10.

13.

Human folliculin delays cell cycle progression through late S and G2/M-phases: effect of phosphorylation and tumor associated mutations.

Laviolette LA, Wilson J, Koller J, Neil C, Hulick P, Rejtar T, Karger B, Teh BT, Iliopoulos O.

PLoS One. 2013 Jul 11;8(7):e66775. doi: 10.1371/journal.pone.0066775. Print 2013.

14.

Cofactor balance by nicotinamide nucleotide transhydrogenase (NNT) coordinates reductive carboxylation and glucose catabolism in the tricarboxylic acid (TCA) cycle.

Gameiro PA, Laviolette LA, Kelleher JK, Iliopoulos O, Stephanopoulos G.

J Biol Chem. 2013 May 3;288(18):12967-77. doi: 10.1074/jbc.M112.396796. Epub 2013 Mar 15.

15.

In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation.

Gameiro PA, Yang J, Metelo AM, Pérez-Carro R, Baker R, Wang Z, Arreola A, Rathmell WK, Olumi A, López-Larrubia P, Stephanopoulos G, Iliopoulos O.

Cell Metab. 2013 Mar 5;17(3):372-85. doi: 10.1016/j.cmet.2013.02.002.

16.

Loss of RBF1 changes glutamine catabolism.

Nicolay BN, Gameiro PA, Tschöp K, Korenjak M, Heilmann AM, Asara JM, Stephanopoulos G, Iliopoulos O, Dyson NJ.

Genes Dev. 2013 Jan 15;27(2):182-96. doi: 10.1101/gad.206227.112. Epub 2013 Jan 15.

17.

Multidimensional liquid chromatography platform for profiling alterations of clusterin N-glycosylation in the plasma of patients with renal cell carcinoma.

Tousi F, Bones J, Iliopoulos O, Hancock WS, Hincapie M.

J Chromatogr A. 2012 Sep 21;1256:121-8. doi: 10.1016/j.chroma.2012.07.066. Epub 2012 Jul 28.

18.

Epithelial cell guidance by self-generated EGF gradients.

Scherber C, Aranyosi AJ, Kulemann B, Thayer SP, Toner M, Iliopoulos O, Irimia D.

Integr Biol (Camb). 2012 Mar;4(3):259-69. doi: 10.1039/c2ib00106c. Epub 2012 Feb 8.

19.

Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia.

Metallo CM, Gameiro PA, Bell EL, Mattaini KR, Yang J, Hiller K, Jewell CM, Johnson ZR, Irvine DJ, Guarente L, Kelleher JK, Vander Heiden MG, Iliopoulos O, Stephanopoulos G.

Nature. 2011 Nov 20;481(7381):380-4. doi: 10.1038/nature10602.

20.

Hypoxia-induced mixed-lineage leukemia 1 regulates glioma stem cell tumorigenic potential.

Heddleston JM, Wu Q, Rivera M, Minhas S, Lathia JD, Sloan AE, Iliopoulos O, Hjelmeland AB, Rich JN.

Cell Death Differ. 2012 Mar;19(3):428-39. doi: 10.1038/cdd.2011.109. Epub 2011 Aug 12.

21.

Immunoaffinity enrichment and liquid chromatography-selected reaction monitoring mass spectrometry for quantitation of carbonic anhydrase 12 in cultured renal carcinoma cells.

Rafalko A, Iliopoulos O, Fusaro VA, Hancock W, Hincapie M.

Anal Chem. 2010 Nov 1;82(21):8998-9005. doi: 10.1021/ac101981t. Epub 2010 Oct 11.

22.

The connectivity map links iron regulatory protein-1-mediated inhibition of hypoxia-inducible factor-2a translation to the anti-inflammatory 15-deoxy-delta12,14-prostaglandin J2.

Zimmer M, Lamb J, Ebert BL, Lynch M, Neil C, Schmidt E, Golub TR, Iliopoulos O.

Cancer Res. 2010 Apr 15;70(8):3071-9. doi: 10.1158/0008-5472.CAN-09-2877. Epub 2010 Mar 30.

23.

The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha.

Zhong L, D'Urso A, Toiber D, Sebastian C, Henry RE, Vadysirisack DD, Guimaraes A, Marinelli B, Wikstrom JD, Nir T, Clish CB, Vaitheesvaran B, Iliopoulos O, Kurland I, Dor Y, Weissleder R, Shirihai OS, Ellisen LW, Espinosa JM, Mostoslavsky R.

Cell. 2010 Jan 22;140(2):280-93. doi: 10.1016/j.cell.2009.12.041.

24.

Small-molecule inhibitors of HIF-2a translation link its 5'UTR iron-responsive element to oxygen sensing.

Zimmer M, Ebert BL, Neil C, Brenner K, Papaioannou I, Melas A, Tolliday N, Lamb J, Pantopoulos K, Golub T, Iliopoulos O.

Mol Cell. 2008 Dec 26;32(6):838-48. doi: 10.1016/j.molcel.2008.12.004.

25.

Case records of the Massachusetts General Hospital. Case 17-2008. A 63-year-old man with metastatic renal-cell carcinoma.

Michaelson MD, Iliopoulos O, McDermott DF, McGovern FJ, Harisinghani MG, Oliva E.

N Engl J Med. 2008 May 29;358(22):2389-96. doi: 10.1056/NEJMcpc0802449. No abstract available.

PMID:
18509125
26.

Hypoxia-inducible factor-2alpha: effect on radiation sensitivity and differential regulation by an mTOR inhibitor.

Bhatt RS, Landis DM, Zimmer M, Torregrossa J, Chen S, Sukhatme VP, Iliopoulos O, Balk S, Bubley GJ.

BJU Int. 2008 Aug;102(3):358-63. doi: 10.1111/j.1464-410X.2008.07558.x. Epub 2008 Apr 3.

27.

Molecular biology of renal cell cancer and the identification of therapeutic targets.

Iliopoulos O.

J Clin Oncol. 2006 Dec 10;24(35):5593-600. Review.

PMID:
17158545
28.

Case records of the Massachusetts General Hospital. Case 23-2006. A 36-year-old man with numbness in the left [corrected] hand and hypertension.

Iliopoulos O, Chan-Smutko G, Gonzalez RG, Louis DN, Stone JR.

N Engl J Med. 2006 Jul 27;355(4):394-402. No abstract available. Erratum in: N Engl J Med. 2006 Sep 14;355(11):1184.

PMID:
16870919
29.

Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells.

Mizukami Y, Jo WS, Duerr EM, Gala M, Li J, Zhang X, Zimmer MA, Iliopoulos O, Zukerberg LR, Kohgo Y, Lynch MP, Rueda BR, Chung DC.

Nat Med. 2005 Sep;11(9):992-7. Epub 2005 Aug 28. Erratum in: Nat Med. 2006 Feb;12(2):253.

PMID:
16127434
30.

Molecular markers for early detection of renal carcinoma: investigative approach.

Skates S, Iliopoulos O.

Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6296S-301S. Review.

31.

Innovations and challenges in renal cancer: consensus statement from the first international conference.

Atkins MB, Avigan DE, Bukowski RM, Childs RW, Dutcher JP, Eisen TG, Figlin RA, Finke JH, Flanigan RC, George DJ, Goldberg SN, Gordon MS, Iliopoulos O, Kaelin WG Jr, Linehan WM, Lipton A, Motzer RJ, Novick AC, Stadler WM, Teh BT, Yang JC, King L.

Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6277S-81S. Review. No abstract available.

32.

Hypoxia-inducible factor-1-independent regulation of vascular endothelial growth factor by hypoxia in colon cancer.

Mizukami Y, Li J, Zhang X, Zimmer MA, Iliopoulos O, Chung DC.

Cancer Res. 2004 Mar 1;64(5):1765-72.

33.

Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors.

Zimmer M, Doucette D, Siddiqui N, Iliopoulos O.

Mol Cancer Res. 2004 Feb;2(2):89-95.

34.

Molecular genetics of kidney cancer.

Zimmer M, Iliopoulos O.

Cancer Treat Res. 2003;116:3-27. Review. No abstract available.

PMID:
14650823
35.

How many pathways to pheochromocytoma?

Neumann HP, Hoegerle S, Manz T, Brenner K, Iliopoulos O.

Semin Nephrol. 2002 Mar;22(2):89-99. Review.

PMID:
11891502
36.

von Hippel-Lindau disease: genetic and clinical observations.

Iliopoulos O.

Front Horm Res. 2001;28:131-66. Review. No abstract available.

PMID:
11443850
37.

Genetic and clinical aspects of familial renal neoplasms.

Iliopoulos O, Eng C.

Semin Oncol. 2000 Apr;27(2):138-49. Review.

PMID:
10768593
38.

Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase.

Kamura T, Koepp DM, Conrad MN, Skowyra D, Moreland RJ, Iliopoulos O, Lane WS, Kaelin WG Jr, Elledge SJ, Conaway RC, Harper JW, Conaway JW.

Science. 1999 Apr 23;284(5414):657-61.

39.

von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids.

Lieubeau-Teillet B, Rak J, Jothy S, Iliopoulos O, Kaelin W, Kerbel RS.

Cancer Res. 1998 Nov 1;58(21):4957-62.

40.

pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation.

Iliopoulos O, Ohh M, Kaelin WG Jr.

Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11661-6.

41.

Functions of the von Hippel-Lindau tumour suppressor protein.

Kaelin WG, Iliopoulos O, Lonergan KM, Ohh M.

J Intern Med. 1998 Jun;243(6):535-9. Review.

42.

The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix.

Ohh M, Yauch RL, Lonergan KM, Whaley JM, Stemmer-Rachamimov AO, Louis DN, Gavin BJ, Kley N, Kaelin WG Jr, Iliopoulos O.

Mol Cell. 1998 Jun;1(7):959-68.

43.

Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2.

Lonergan KM, Iliopoulos O, Ohh M, Kamura T, Conaway RC, Conaway JW, Kaelin WG Jr.

Mol Cell Biol. 1998 Feb;18(2):732-41.

44.

The molecular basis of von Hippel-Lindau disease.

Iliopoulos O, Kaelin WG Jr.

Mol Med. 1997 May;3(5):289-93. Review. No abstract available.

45.

Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues.

Corless CL, Kibel AS, Iliopoulos O, Kaelin WG Jr.

Hum Pathol. 1997 Apr;28(4):459-64.

PMID:
9104946
46.

Regulation of vascular endothelial growth factor by hypoxia and its modulation by the von Hippel-Lindau tumor suppressor gene.

Levy AP, Levy NS, Iliopoulos O, Jiang C, Kaplin WG Jr, Goldberg MA.

Kidney Int. 1997 Feb;51(2):575-8. Review.

47.

Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein.

Iliopoulos O, Levy AP, Jiang C, Kaelin WG Jr, Goldberg MA.

Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10595-9.

48.

Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C.

Kibel A, Iliopoulos O, DeCaprio JA, Kaelin WG Jr.

Science. 1995 Sep 8;269(5229):1444-6.

PMID:
7660130
49.

Tumour suppression by the human von Hippel-Lindau gene product.

Iliopoulos O, Kibel A, Gray S, Kaelin WG Jr.

Nat Med. 1995 Aug;1(8):822-6.

PMID:
7585187
50.

Acute renal failure following binge drinking and nonsteroidal antiinflammatory drugs.

Wen SF, Parthasarathy R, Iliopoulos O, Oberley TD.

Am J Kidney Dis. 1992 Sep;20(3):281-5.

PMID:
1519610

Supplemental Content

Loading ...
Support Center